2020 – State Expert Center of the Ministry of Health of Ukraine

MOXIFLOXACIN-TEVA_ LEVOFLOXACIN-TEVA

11.01.2021 3697

Letter to healthcare professionals on the risk of heart valve regurgitation with systemic or inhaled fluoroquinolones. Contains information on risk factors, restrictions on prescribing to patients at risk, and recommendations to seek medical help immediately. generated automatically

LEVOFLOXACIN-NOVOFARM_ CIPROFLOXACIN-NOVOFARM

11.01.2021 2314

Information letter to healthcare professionals on new data on the risk of heart valve regurgitation and insufficiency with the use of systemic and inhaled fluoroquinolones, with recommendations on benefit/risk assessment and patient monitoring. compiled automatically

BIOCERULIN®

11.01.2021 2760

Information letter for healthcare professionals on the increased risk of immunogenicity in response to ceruloplasmin: possible formation of antibodies to biological products, recommendations for patient monitoring, and reporting of adverse reactions. generated automatically

LEVOFLOXACIN EURO_ LEVOFLOXACIN_ MOXIMAC

04.01.2021 2558

Information letter for healthcare professionals on the risks of systemic and inhaled fluoroquinolones, in particular aortic aneurysm and dissection, and aortic and mitral valve regurgitation. compiled automatically

HYRIMOZ 40 MG

30.12.2020 3905

Patient leaflet on the safe use of a medicinal product for treating children with immune diseases. Contains information on possible side effects, vaccination and the need for physician supervision during and after treatment. generated automatically

LENALIDOMIDE-TEVA

28.12.2020 2749

Guide for healthcare professionals on the use of Lenalidomide-Teva and on minimizing the risks of teratogenicity and secondary malignancies. Contains safety recommendations, patient counseling, pregnancy prevention and a physician checklist. compiled automatically

ATOVAX®

21.12.2020 3200

Information letter to healthcare professionals on the risk of heart valve regurgitation and insufficiency associated with the use of fluoroquinolones for systemic and inhalation use, with recommendations on benefit-risk assessment and reporting of adverse reactions. generated automatically

POLIMIK®

21.12.2020 2860

Information letter to healthcare professionals on the increased risk of regurgitation and heart valve insufficiency with the use of systemic and inhaled fluoroquinolones, including as part of a combination medicinal product. Contains recommendations on assessing the benefit-risk balance and the procedure for reporting adverse reactions. generated automatically

ESBRIET®

21.12.2020 2697

Safety instructions for physicians when prescribing the medicinal product, containing a list of risk minimization measures: liver function monitoring, prevention of photosensitivity, and the procedure for reporting adverse reactions. generated automatically

OFLOXIN® 200

21.12.2020 2261

Information letter for health care professionals about a new risk of heart valve regurgitation and insufficiency with the use of systemic and inhaled fluoroquinolones, in particular ofloxacin. Contains recommendations on assessing the benefit-risk balance and informing patients about symptoms. generated automatically